読み込み中
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
前日終値
$38.26
+$0.73 · +1.95%
市場前
$37.78
−$0.48 · -1.25%
10月8日 9:03 ET
日中の時刻はETです。市場データは遅延する場合があります。
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
日中レンジ
現在 $38.26
52週レンジ
現在 $38.26
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
99
大幅な割安
センチメント
52
まちまち
リスク
34
中程度のリスク
モメンタム
45
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
日中レンジ
現在 $38.26
52週レンジ
現在 $38.26
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（DKK） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3090.64億 DKK | 2904.03億 DKK | 2322.61億 DKK | 1769.54億 DKK | 1408億 DKK |
| 売上原価 | 587.88億 DKK | 445.22億 DKK | 357.65億 DKK | 284.48億 DKK | 236.58億 DKK |
| 粗利益 | 2502.76億 DKK | 2458.81億 DKK | 1964.96億 DKK | 1485.06億 DKK | 1171.42億 DKK |
| 研究開発 | 520.39億 DKK | 480.62億 DKK | 324.43億 DKK | 240.47億 DKK | 177.72億 DKK |
| 販売・一般管理 | 702.79億 DKK | 673.77億 DKK | 615.98億 DKK | 506.84億 DKK | 410.58億 DKK |
| 営業費用 | 1226.18億 DKK | 1175.42億 DKK | 939.22億 DKK | 736.97億 DKK | 584.98億 DKK |
| 受取利息 | 12.69億 DKK | 18.38億 DKK | 10.69億 DKK | 2.39億 DKK | 2.31億 DKK |
| 支払利息 | 42.07億 DKK | 16.4億 DKK | 5.42億 DKK | 3.78億 DKK | 2.89億 DKK |
| 減価償却費と償却費 | 219.82億 DKK | 191.07億 DKK | 94.13億 DKK | 73.62億 DKK | 60.25億 DKK |
| 営業利益 | 1276.58億 DKK | 1283.39億 DKK | 1025.74億 DKK | 748.09億 DKK | 586.44億 DKK |
| 純利益 | 1024.34億 DKK | 1009.88億 DKK | 836.83億 DKK | 555.25億 DKK | 477.57億 DKK |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$44.67
上昇余地（16.75%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年9月20日 | 2:1 | — | — |
株式分割 | 2014年1月9日 | 5:1 | — | — |
株式分割 | 2007年12月17日 | 2:1 | — | — |
株式分割 | 2001年4月11日 | 5:2 | — | — |
株式分割 | 1994年4月18日 | 4:1 | — | — |
発効済み 2023年9月20日
2:1
発効済み 2014年1月9日
5:1
発効済み 2007年12月17日
2:1
発効済み 2001年4月11日
5:2
発効済み 1994年4月18日
4:1
この株式へのエクスポージャーを報告している上場投資信託です。
VanEck Pharmaceutical ETFPPH5693.44万5.61%10.28億 USD0.36%$109.49+1.22%
Avantis International Equity ETFAVDE5126.68万0.27%192.77億 USD0.23%$89.48-1.21%
First Trust WCM International Equity ETFWCMI3054.39万1.44%21.19億 USD0.85%$18.99-1.58%
Invesco International Dividend Achievers ETFPID1662.8万1.95%8.54億 USD0.53%$21.49-0.42%
Hartford Multifactor Developed Markets (ex-US) ETFRODM1100.72万0.68%16.22億 USD0.29%$40.55-0.83%
Avantis International Large Cap Value ETFAVIV1089.87万0.53%20.2億 USD0.25%$78.70-1.08%
ActivePassive International Equity ETFAPIE834.4万0.73%11.83億 USD0.45%$38.58-1.25%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM645.52万11.45%5639.56万 USD0.59%$30.0942-0.04%VanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEFirst Trust WCM International Equity ETFWCMIInvesco International Dividend Achievers ETFPIDHartford Multifactor Developed Markets (ex-US) ETFRODMAvantis International Large Cap Value ETFAVIVActivePassive International Equity ETFAPIERoundhill Investments - GLP-1 & Weight Loss ETFOZEMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
